Who is sponsoring ToPP-UP?

ToPP-UP is sponsored by University of Florida.

What condition does ToPP-UP study?

ToPP-UP studies Use of Prescription Medications, Pharmacogenetic Testing.

What drugs are being tested in ToPP-UP?

Interventions: Panel-based pharmacogenetic genotyping.

What is the status of ToPP-UP?

ToPP-UP is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2025-11-17 · How we verify

Trial of Preemptive Pharmacogenetics in Underserved Patients (ToPP-UP)

NCT05141019 NA ACTIVE_NOT_RECRUITING

This proposed research is relevant to human health because preemptive clinical pharmacogenetic testing may improve the personalization of drug therapy which should improve patient outcomes. Better understanding of the effectiveness and feasibility of preemptive clinical pharmacogenetic testing will inform when and how this innovative healthcare technology is implemented into clinical care. To ensure equitable dissemination in all patient populations, such data is also needed in racial minorities and other traditionally underserved populations. The combined proposed research are relevant to the parts of the NIH's mission pertaining to protecting and improving health and developing scientific human resources that will ensure the Nation's capability to prevent and treat disease.

Details

Lead sponsor	University of Florida
Phase	NA
Status	ACTIVE_NOT_RECRUITING
Enrolment	492
Start date	Mon Aug 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jun 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Use of Prescription Medications
Pharmacogenetic Testing

Interventions

Panel-based pharmacogenetic genotyping

Countries

United States